We examined the association between C-reactive protein (CRP) and left ventricular mass index (LVMI), and investigated prospectively the incidence of cardiovascular disease (CVD) in asymptomatic subjects with essential hypertension. A total of 629 subjects (mean age 62 years, 51% female) free of prior CVD were included in this study. In cross-sectional analysis at baseline, patients were divided into three groups according to serum CRP levels: <1, 1 to 2, and >2 mg/L. In multivariate analysis, LVMI increased in a stepwise fashion with increasing CRP levels in both men (127.2 ± 2.9, 138.7 ± 4.1, 141.8 ± 3.5 g/m 2 , respectively; 
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Introduction
Hypertension is a central risk factor for cardiovascular disease (CVD), and the cardiovascular prognosis in patients with hypertension depends not only on the level of blood pressure (BP), but also on the presence of associated risk factors. Inflammatory processes are now recognized to play a fundamental role in atherogenesis ( 1 ) . In addition, basic and clinical data suggest the possible involvement of inflammation in the genesis of hypertension and that hypertension in turn induces a proinflammatory response ( 2 -4 ). C-reactive protein (CRP), a marker of the reactant plasma protein component of the inflammatory response, has been found to be a robust predictor of the development of CVD in several large epidemiological studies ( 5 -10 ) . The guidelines from the European Society of Hypertension and the European Society of Cardiology (ESH-ESC) ( 11 ), and the Centers for Disease Control and Prevention/American Heart Association (CDC/AHA) ( 12 ) also stress the importance of measuring CRP in primary prevention. On the other hand, an elevated CRP level is affected by or linked to hypertension and many metabolic factors such as insulin resistance ( 13 , 14 ) , all of which are also associated with left ventricular hypertrophy (LVH). Previous reports have examined the association between CRP and left ventricular (LV) mass, but the results obtained are controversial ( 15 -19 ) . Thus, the clinical importance of CRP in LVH has not been fully elucidated. In this study, we investigated the potential interrelationships between CRP and LV mass index (LVMI) in patients with essential hypertension by using the clinical cut-off levels of CRP. We further sought to evaluate the interrelationships between CRP, LVMI, and incidence of CVD in asymptomatic hypertensive patients. In addition, we attempted to determine whether CRP might provide useful prognostic information to enhance that by provided by LVH.
Methods

Study Subjects
From March 1997 to March 2004, a total of 629 essential hypertensive patients who had good-quality echocardiographic recordings were consecutively enrolled in this study and monitored for 31.6 ± 0.8 months. All subjects were selected from patients who were admitted and underwent medical investigation including a general check-up at the National Cardiovascular Center in Osaka, Japan. Hypertension was defined as systolic BP (SBP) ≥ 140 mmHg and/or diastolic BP (DBP) ≥ 90 mmHg on repeated measurements, or receipt of antihypertensive treatment. Diabetes mellitus was defined according to the American Diabetes Association criteria ( 20 ) . Smoking status was determined by interview, and defined as currently smoking or not. Ischemic heart disease was defined as a 75% or greater organic stenosis of at least one major coronary artery as confirmed by coronary angiography, or a history of myocardial infarction or percutaneous transluminal coronary angioplasty. Exclusion criteria included ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association [NYHA] class II or greater), old cerebral infarction, history of transient ischemic attack, secondary hypertension, receipt of hormone replacement therapy and/or an anti-inflammatory drug (aspirin or nonsteroidal anti-inflammatory drug [NSAID]), chronic infection, and cancer. Participants with moderate or severe aortic or mitral regurgitation or a heart rate > 100 bpm were also excluded. All procedures in the present study were carried out in accordance with institutional and national ethical guidelines for human studies. All subjects enrolled in this study were Japanese, and all gave informed consent to participate in this study.
Baseline Clinical Characteristics
After fasting overnight, BP was measured with an appropriate arm cuff and a mercury column sphygmomanometer on the left arm after a resting period of at least 10 min in the supine position. After BP measurement, venous blood sampling was performed in all subjects. Height and body weight were measured, and body mass index was calculated. The following parameters were also determined: total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-chol), and CRP levels. High-sensitivity CRP was measured by a validated latex-enhanced immunonephelometric assay (sensitivity 0.1 mg/L; Roche Diagnostics, Indianapolis, USA). If the CRP level was > 10 mg/L, the test was repeated.
Echocardiographic Methods and Calculation of Derived Variables
Imaging and Doppler echocardiography were performed in all participants in this study, as previously described ( 21 , 22) . Studies were performed using phased-array echocardiography with M-mode, 2-dimensional, pulsed, and color-flow Doppler capabilities. LV internal dimension and septal and posterior wall thickness were measured at end-diastole and end-systole according to the American Society of Echocardiography recommendations (23) . Color-flow Doppler recordings were used to check for aortic and mitral regurgitation, as previously described (24) . End-diastolic dimensions were used to calculate LV mass by a previously reported formula (25) . LV mass was considered an unadjusted variable, and was normalized by body surface area and expressed as LVMI. The LV diastolic filling pattern was recorded from the apical transducer position with the subject in the left lateral decubitus position, with the sample volume situated between the mitral leaflet tips. The leading edge of the transmitral Doppler flow pattern was traced to derive the peak of early diastolic and atrial phase LV filling, their ratio (E-A ratio), and the deceleration time of early diastolic LV filling (DcT).
Pulmonary venous flow velocities were recorded by placing a sample volume of about 1 cm into the right superior pulmonary vein (26) . The variables derived were the peak pulmonary venous flow during ventricular systole (PVs), that during ventricular diastole, and their ratio (S-D ratio). When a biphasic PVs was detected, the highest peak velocity was used (26) . All measurements were performed by one trained investigator who was blinded to the clinical data of the subjects.
Clinical End Points
For survival analysis, observation began on the day of echocardiography, and all subjects were followed at the National Cardiovascular Center in Osaka, and treated by implementation of standard lifestyle and pharmacologic mea-sures. All subjects were periodically referred to our institution for BP control and other diagnostic procedures. CVD events of interest in this study were: myocardial infarction confirmed by electrocardiographic changes, coronary angiography and/ or myocardial scintigraphy findings, stroke confirmed by clinical symptoms, computed tomography and magnetic resonance angiography and/or cerebrovascular angiography findings, peripheral arterial occlusive disease confirmed by clinical symptoms, magnetic resonance angiography and/or peripheral angiography (the presence of ≥ 1 stenosis of ≥ 50% in the iliac, femoral, popliteal, or crural arteries), and CHF requiring hospitalization. CHF was defined by the Framingham Heart Study criteria (27) . These criteria require the simultaneous presence of at least two major criteria, or one major criterion in conjunction with two minor criteria, to establish a diagnosis of CHF, and have been validated previously (28) . The cause of death was classified as CVD if there was sudden death from CVD, by an independent review panel of physicians who were unaware of the echocardiographic and clinical findings. Events that were more equivocal, such as unrecognized myocardial infarction, were not included as CVD for this analysis. Furthermore, patients with clinical evi- p<0.01. CRP, C-reactive protein; LVMI, left ventricular mass index; E-A ratio, the ratio of the peak velocity of early diastolic to atrial phase left ventricular filling; DcT, the deceleration time of early diastolic left ventricular filling; S-D ratio, the ratio of the peak pulmonary venous flow during ventricular systole to the during ventricular diastole.
dence of pneumonia or uremia were excluded. For patients who experienced multiple non-fatal episodes of CVD, the analysis included only the first event.
Statistical Analysis
Parametric data are presented as the means±SEM. Total subjects were divided into three groups for each sex using the clinical cut-off levels of CRP of < 1, 1 to 2, and > 2 mg/L, and then the significance of any differences among groups was evaluated using one-way analysis of variance (ANOVA) with Dunnett's multiple comparison posttest. Multiple regression models were used to assess the relationship between LVMI and CRP level categories after adjustment for potential confounding factors affecting LVMI. Because of the right skew in CRP distribution, levels of CRP were log-transformed to examine the significance of any difference among groups.
Event-free survival analysis was performed with the Kaplan-Meier method to plot the cumulative incidence of CVD according to CRP level (< 1 or ≥ 1 mg/L) or the absence or presence of LVH (LVMI > 125 g/m 2 for men and > 110 g/ m 2 for women) (11, 29) , and the groups were compared by the Mantel log rank test. The cut-off level of CRP of 1 mg/L was based both on the AHA/CDC (12) and the ESH-ESC (11) rec- ommendations in which CRP levels of ≥ 1 mg/L were defined as average-and high-risk groups. Cox proportional hazard analysis was used to examine the association between variables and the cumulative incidence of CVD in crude models. These effects were measured by hazard ratios (HR) and their 95% confidence intervals (CI) based on Cox regression models.
To evaluate combined effects, we divided the total subjects into four groups according to the baseline level of CRP (< 1 or ≥ 1 mg/L) and the absence or presence of LVH. ANOVA with Dunnett's multiple comparison posttest was also used to analyze data among the four groups. Kaplan-Meier curves for event-free survival according to the level of CRP and LVH category were also constructed. The relative risk of CVD events in Cox proportional-hazard analysis was assessed in crude and multivariate models, after accounting for relevant variables using a p value of less than 0.05 as the selection criterion. The cumulative incidence of CVD was calculated using the group with non-LVH/CRP < 1 mg/L as a reference for the others. A p value less than 0.05 was considered statistically significant. All calculations were performed using a standard statistical package (JMP 4.0; SAS Institute, Cary, USA).
Results
Association between CRP and LVMI
Baseline clinical and biochemical characteristics of the study subjects are shown in Table 1 . At baseline, diuretics, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and calcium-channel blockers were used alone or in various combinations in 18.1%, 27.3%, 34.5%, and 68.2% of the study patients, respectively. Male subjects had significantly higher LVMI levels as compared with female subjects (135.6±1.9 vs. 120.1±1.9 g/m 2 ; p< 0.01). p<0.01 vs. LVH/CRP ≥1 mg/L. LVH, left ventricular hypertrophy; CRP, C-reactive protein; BP, blood pressure; HDL-chol, high density lipoprotein cholesterol; LVMI, left ventricular mass index; E-A ratio, the ratio of the peak velocity of early diastolic to atrial phase left ventricular filling; DcT, the deceleration time of early diastolic left ventricular filling; S-D ratio, the ratio of the peak pulmonary venous flow during ventricular systole to the during ventricular diastole; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CVD, cardiovascular disease.
There was a linear increase in LVMI levels as the CRP categories increased; median LVMI levels for those with a CRP level of < 1, 1 to 2, and > 2 mg/L were 128.5, 133.9, and 139.7 in males, and 111.3, 125.1, and 121.8 g/m 2 in females, respectively (both, p for trend < 0.01). Table 2 shows the crude mean levels and SEM ranges of echocardiographic parameters according to CRP category at enrollment. A similar linear increase in the levels of the S-D ratio and DcT, and decrease in the levels of the E-A ratio, were also seen as the levels of CRP category increased. Multivariate analysis including age, body mass index, diabetes, duration of hypertension, SBP and DBP, heart rate, total cholesterol, triglycerides, HDL-chol, and smoking status was performed, and indicated that the 
Predictive Value of CRP and LVMI for CVD
During the follow-up period, 52 patients (8.3%, 19 female) developed CVD. There were 27 subjects with CHF, 12 with stroke, 5 with myocardial infarction, and 2 with peripheral arterial occlusive disease, and 6 patients died of CVD causes. The CRP level and LVMI were significantly higher in patients who developed CVD during the follow-up period than in event-free subjects (CRP: 3.87±0.98 vs. events throughout the follow-up period according to the two groups on the basis of the CRP level (< 1 or ≥ 1 mg/L) and the absence or presence of LVH are plotted in Figs. 1 
Incidence of CVD Jointly with CRP and LVH
To assess the combined effects of CRP and LVH, we constructed survival curves after dividing the total subjects into four groups on the basis of CRP level (< 1 or ≥ 1 mg/L) and the absence or presence of LVH: non-LVH/CRP < 1, non-LVH/CRP ≥ 1, LVH/CRP < 1, and LVH/CRP ≥ 1. The baseline clinical and biochemical characteristics of the study subjects are shown in Table 3 . The group with LVH/CRP ≥ 1 showed a significantly higher prevalence of current smokers and diabetes, significantly lower HDL-chol and E-A ratio than that with LVH/ CRP < 1. Kaplan-Meier curves in the four groups showed significantly poorer event-free survival in subjects with LVH/CRP ≥ 1 (log-rank χ 2 = 28.02, p< 0.001). In Cox regression analysis (Table 4) , the risk for CVD was markedly increased in the group with LVH/CRP ≥ 1 (HR 3.37) compared with the non-LVH/CRP < 1 group. In multivariate Cox regression analysis including age, sex, diabetes, SBP, and HDL-chol, the combination of LVH and CRP ≥ 1 mg/L was an independent predictor of CVD (HR 2.65).
When the analysis was restricted to the subgroup with LVH (n= 362), 45 CVD events occurred during the follow-up period. Even in these subjects, the CRP level was significantly higher in patients who developed CVD during the follow-up period than in event-free subjects (3.82±0.92 vs. 2.02±0.35 mg/L, p< 0.01). The results of the life table analysis of CVD throughout the follow-up period according to the two groups on the basis of CRP level (< 1 or ≥ 1 mg/L) are plotted in Fig. 3 , and these curves show significantly poorer event-free survival in the group with CRP ≥ 1 mg/L. In addition, in Cox regression analysis, CRP ≥ 1 mg/L was associated with a 1.37-fold higher risk of CVD events in the subgroup with LVH (HR 1.37; 95% CI: 1.02-1.85; p= 0.025).
Discussion
Our cross-sectional study revealed a linear relationship between categories of CRP and LVMI, and the relationship was evident even after adjustment for confounding factors by multivariate analysis. In a follow-up study, both high CRP and LVH were significant determinants of CVD events, and the combination of elevated CRP and LVH was a powerful predictor for CVD events. In addition, the present study also demonstrated that, in patients with LVH, CRP had additive predictive value for CVD risk.
The present observation of an independent association between categories of CRP level and LVMI is consistent with previous findings (15, 19) , and the present study extended these observations for CRP to essential hypertension. A raised baseline CRP value has been associated with inflammation, endothelial dysfunction (14) , obesity (14) , the metabolic syndrome (30, 31) , diabetes mellitus (32), insulin resistance (13) , and severity of hypertension (33) , and thus, various metabolic disorders may occur with increasing CRP level, and simultaneously promote an increase in LV mass. On the other hand, local CRP synthesis and secretion by smooth muscle cells, including those of the human coronary artery, have been suggested (34) . It is possible to speculate that CRP may play a more direct role in promoting LVH, including 1) increasing phosphatidylinositol-3 kinase activity (35); 2) upregulating inducible nitric oxide synthase, certain cell signal transduction pathways including the mitogen-activated protein kinase pathway, and nuclear factor κ-B; 3) upregulating angiotensin II type 1 receptor in vascular smooth muscle cells, and directly quenching the production of nitric oxide by endothelial cells (2, 4) , resulting in increased production of endothelin-1 (34, 36) ; and 4) elevation of von Willebrand factor (37) , which is known to be associated with endothelial dysfunction. Thus, cardiac hypertrophy may be, at least in part, attributable to an increase in CRP itself, via activated transcriptional regulatory mechanisms, proinflammatory and proatherogenic effects, and stimulation of endothelial dysfunction.
Previous studies have demonstrated that CRP evaluation adds prognostic value to metabolic syndrome (38), higher fibrinogen (39), or higher BP (3) in terms of CVD risk. The present prospective cohort of initially asymptomatic essential hypertensive patients revealed the importance of measuring CRP in addition to LVMI by echocardiography, and also showed that the combined evaluation of both CRP and LVMI was superior as a method of risk detection compared to measurement of either biologic marker alone. In addition, the present findings suggest that, in the presence of LVH, CRP adds important and independent prognostic information in terms of CVD risk. This result may have been due to the fact that our subjects with higher LVMI and CRP had more severe dyslipidemia, as well as a higher prevalence of current-smoking and diabetes, which are established risk factors for CVD. On the other hand, several mechanisms have been proposed to account for the association between CRP and CVD, including: 1) induction of loss of vasoreactivity, expression of adhesion molecules and secretion of chemoattractants in the endothelium; 2) increases in tissue factor secretion, promo-tion of monocyte chemotaxis and adhesion to endothelial cells, reactive oxygen species release, matrix metalloproteinase-1 induction, and promotion of oxidized low-density lipoprotein uptake, which leads to increased foam cell formation; 3) increased expression of angiotensin II type 1 receptor mRNA and protein expression as well as increased vascular smooth muscle cell proliferation and migration; 4) binding of CRP to enzymatically modified low density lipoprotein, with the resulting complex showing increased ability to convert C3 and activate its complement (34, 36) ; and 5) attenuation of the production of nitric oxide and prostacyclin by endothelial cells (2, 4) . Furthermore, our results showed that more severe impairment of relaxation was observed in subjects with high LVMI and high CRP, and this "impaired relaxation" is known to be associated with increased risk of CVD (40) . In addition, a significant association between the categories of CRP and the E-A ratio, DcT, and S-D ratio, markers of relaxation impairment, was observed in this study, and a high CRP level may contribute to the progression of LV dysfunction. Consequently, we propose that, in subjects with LVH, activation of the renin-angiotensin system, activation of proatherogenic and proinflammatory responses in cardiovascular cells, and more impaired relaxation may occur with increasing CRP level, and enhance the risk for CVD.
It is not possible to conclude whether CRP stimulates higher LVMI or whether CRP is increased before the development of LVH. Indeed, it is possible that both these effects work in tandem in CVD. In addition, this study had missing baseline data and information on other potentially important characteristics, such as alcohol intake and physical activity, which are also associated with a lower CRP level. Finally, we did not account for the duration of hypertension prior to treatment at our institution. Because our data were obtained in subjects with already-treated essential hypertension at the start of the study, these results could underestimate the involvement of BP itself in the development of LVH and CVD events.
In conclusion, in essential hypertensive subjects initially free of CVD, CRP showed a significant association with LVMI. In those with LVH, the baseline CRP level added clinically relevant prognostic information concerning CVD risk. In hypertensive as well as LVH subjects, assessment of CRP levels may help to refine CVD risk stratification.
